Clinical Trials
31 trialsCOAST
Medical University of South Carolina
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
National Cancer Institute (NCI)
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Georgetown University
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
Ruijin Hospital
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
City of Hope Medical Center
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
M.D. Anderson Cancer Center
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
BMS-CA180105
University of California, San Diego
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Bristol-Myers Squibb
Dasatinib (Sprycelâ„¢) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
University of Ulm
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
M.D. Anderson Cancer Center
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
A Phase I/II Study of Dasatinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Bristol-Myers Squibb
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
Bristol-Myers Squibb
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Bristol-Myers Squibb
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Bristol-Myers Squibb